SEARCH RESULT

Total Matching Records found : 426

ACTA will make life saving drugs costlier for the poor-Rachit Ranjan

Joseph Munyi, a Kenyan citizen, has been living with HIV for 8 years and, much like other HIV patients, is unemployed. He has been receiving his medication free of charge on account of government programmes and outreach programmes of Medicine Sans Frontieres. His medication comes in the form of generic drugs. However, this situation may not last long as economic interests of few may end up impeding many a public spirited...

More »

A healthier India: Need to resolve conflict between drug price controls, innovation and affordable healthcare-David Taylor

The debate about essential-medicine pricing and access in India illustrates the difficulties inherent in establishing policies that serve conflicting public interests in achieving goals such as caring well and ensuring safety for all, while also pursuing financially-sustainable success in scientific innovation and trade. It highlights problems facing those interested in continuing drug and vaccines development and ensuring that, once marketed, such products contribute effectively to improving public health. Modern pharmaceuticals...

More »

Bayer to challenge Cipla’s decision to cut price of cancer drug

-PTI German pharma major Bayer has charged that Indian generic drugmaker Cipla had breached its patent rights by slashing the price of a generic version of its patent-protected cancer drug Nexavar last week. Bayer Pharma has not given its consent to Cipla to launch its generic Sorafenib (sold under the brand name Nexavar) and the company’s decision to cut the price of the life-extending kidney and liver cancer drug “is a clear...

More »

Cipla shocks rivals by slashing cancer drug prices up to 75%-Divya Rajagopal

Fighting cancer has just become less expensive for millions of Indian patients. More than 12 years after he electrified the pharma industry by taking on powerful global giants in his quest to supply cheap anti-AIDS drugs, Cipla promoter YK Hamied is back donning the role of a price warrior. This time, his attention is on anti-cancer drugs. On Thursday, Cipla cut prices of key cancer drugs by nearly 75%, an astounding,...

More »

Study Shows Unique ID’s Reach to India’s Poor-Amol Sharma

When India embarked on its “unique ID” project in the fall of 2010, pledging to distribute unique 12-digit numbers to 1.2 billion people, the hope was that hundreds of millions of Indians who don’t have a passport, driver’s license or other credible identity document would get one – and with it, a ticket to essential government and private sector services. A new survey led by Arun Sundararajan, a professor at New...

More »

Video Archives

Archives

share on Facebook
Twitter
RSS
Feedback
Read Later

Contact Form

Please enter security code
      Close